Ocular Effects of Topical and Systemic Corticosteroids

David, DavidS.; Berkowitz, JeromeS

doi:10.1016/s0140-6736(69)92454-4

Cited by 86 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroid use should be as minimal as possible, since duration of therapy is the primary determinant of cataract production [9,33] although the patient's underlying disease, [6] individual susceptibility, [34,35] and ethnicity (Hispanics may be affected more than are Whites or African-Americans) [36,37] also may be influential.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Corticosteroid Therapy and Cataract in Man

Branco¹,

Branco²,

Maibach³

2002

Journal of Toxicology: Cutaneous and Ocular Toxicology

View full text Add to dashboard Cite

Introduction: It is well established that the use of corticosteroids is associated with the development of cataracts (posterior subcapsular cataract). This type of cataract is also related with cataract found in patients with atopic dermatitis. Since many patients use topical corticoids for treatment of skin diseases, it may be possible that an association between cataract (and glaucoma) and corticosteroids' treatment exists. Objective: Relating the cutaneous corticosteroid use and the development of cataract in patients with dermatologic disease. Material and Methods: A review of literature using Medline and citations in articles to obtain this case-report series. Results: Seven patients (all men) developed cataract while using topical corticosteroids for skin diseases. Three of these seven patients also presented with glaucoma, possibly as a complication of topical corticoid on the face. Conclusion: Cataract seems to be related to topical steroids' use in periocular skin, but their real importance needs to be evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous Corticosteroid Therapy and Cataract in Man

Branco¹,

Branco²,

Maibach³

2002

Journal of Toxicology: Cutaneous and Ocular Toxicology

View full text Add to dashboard Cite

show abstract

“…Risk factors include preexisting glaucoma, positive family history, diabetes mellitus, and myopia [27,28].…”

Section: Glaucomamentioning

confidence: 99%

“…Ophthalmological adverse effects of corticosteroids other than cataract and glaucoma must be warranted. Other well documented ocular complications include decreased acuity from acute myopia, subconjunctival and retinal hemorrhages, and sclera discoloration and thinning [27,28].…”

Section: Ophthalmological Adverse Effects Of Corticosteroidsmentioning

confidence: 99%

See 1 more Smart Citation

Ophthalmologic manifestations commonly misdiagnosed as demyelinating events in multiple sclerosis patients

Simão

2010

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Ocular complications include reversible elevations in intraocular pressure, especially in patients with myopia and diabetes, and posterior subcapsular cataracts, mainly in patients receiving higher doses over 1 year (David & Berkowitz 1969).…”

Section: Adverse Effectsmentioning

confidence: 99%

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

Hanauer

Stathopoulos

1991

Drug Safety

View full text Add to dashboard Cite

Although the aetiology of inflammatory bowel disease remains elusive, many agents are available for the control of symptoms and inflammation. Knowledge of drug pharmacology, indications and side effects is essential to ensure the best possible clinical care while minimising toxicity and inappropriate use. Sulfasalazine consists of sulfapyridine linked to mesalazine (5-aminosalicylic acid) via an azobond. Its use is indicated in the treatment of mild to moderately active ulcerative colitis and in the prevention of relapse in patients with quiescent disease. Patients with mild to moderate colonic or ileocolonic Crohn's disease also benefit from this drug, as do a proportion of patients with isolated small bowel disease. Sulfasalazine has not been uniformly effective in preventing relapse in Crohn's disease, although many clinicians continue its use in patients who respond initially. A high incidence of side effects which limit therapy include intolerance, hypersensitivity reactions and impairment of male infertility. The newer aminosalicylates offer targeted delivery of mesalazine to the bowel, with fewer side effects. Topical mesalazine has proved extremely effective in patients with distal ulcerative colitis; oral forms are effective in the treatment of mild to moderately active ulcerative colitis and in relapse. Both types appear to be effective in the treatment of Crohn's disease, and possibly in preventing relapse. There is no current clinical advantage of one mesalazine preparation over another, nor is there an indication for their use in sulfasalazine-treated patients who have satisfactory response without adverse effects. Corticosteroids are indicated for more severe disease activity where the aminosalicylates have limited efficacy-specifically to induce remission in patients with severe or refractory ulcerative colitis or Crohn's disease. They should not be used to maintain disease remission or in the prevention of postoperative recurrence. Topical corticosteroids allow their local use in distal colitis with minimal systemic side effects. Long term use is limited by side effects, many of which are dose related, although alternate-day therapy may lessen the incidence. Immunosuppressive agents are beneficial for the treatment of refractory inflammatory bowel disease unresponsive to other medications, and may also facilitate the withdrawal of steroids in refractory patients. Mercaptopurine has an added benefit in the treatment of Crohn's disease fistulae; the role of cyclosporin in bowel disease has not been established and its use cannot currently be recommended. The potential toxicity of immunosuppressive agents warrants careful consideration of their use by both physician and patient. Metronidazole is indicated for the treatment of mild to moderate Crohn's disease, including perineal disease. Common side effects include peripheral neuropathy and nausea.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Ocular Effects of Topical and Systemic Corticosteroids

Cited by 86 publications

References 32 publications

Cutaneous Corticosteroid Therapy and Cataract in Man

Cutaneous Corticosteroid Therapy and Cataract in Man

Ophthalmologic manifestations commonly misdiagnosed as demyelinating events in multiple sclerosis patients

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

Contact Info

Product

Resources

About